Jazz Pharma licenses Luvox in USA
Belgian group Solvay Pharmaceuticals and USA-based drugmaker Jazz Pharmaceuticals have established an agreement which grants the latter marketing rights to the an extended-release formulation of the former's drug Luvox (fluvoxamine maleate) in the USA. The deal is contingent on Food and Drug Administration approval.
Solvay explained that the New Drug Application it submitted to the FDA in April 2006 requests clearance for use of the product in the treatment of two psychiatric conditions, namely generalized social anxiety disorder and obsessive compulsive disorder. The firm added that the NDA was supported by clinical data from a series of safety and efficacy trials that enrolled 600 patients.
Luvox key to Solvay's neuroscience portfolio
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze